Appropriate dosing of sugammadex to reverse deep rocuronium-induced neuromuscular blockade in morbidly obese patients

Anaesthesia

Volumn 71, Issue 3, 2016, Pages 265-272

  Loupec, T ^a   Frasca, D ^a   Rousseau, N ^a   Faure, J P ^a   Mimoz, O ^a   Debaene, B ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROPOFOL; REMIFENTANIL; ROCURONIUM; SUGAMMADEX; THIOPENTAL; ANDROSTANE DERIVATIVE; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

ACCELEROMETRY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ELECTIVE SURGERY; FEMALE; GENERAL ANESTHESIA; HUMAN; LOW DRUG DOSE; MALE; MORBID OBESITY; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR MONITORING; POST TETANIC POTENTIATION; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; ELECTROSTIMULATION; MIDDLE AGED; MYOGRAPHY; OBESITY, MORBID; YOUNG ADULT;

ACCELEROMETRY; ADOLESCENT; ADULT; AGED; ANDROSTANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTRIC STIMULATION; FEMALE; GAMMA-CYCLODEXTRINS; HUMANS; MALE; MIDDLE AGED; MYOGRAPHY; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS; OBESITY, MORBID; YOUNG ADULT;

EID: 84959182021     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/anae.13344     Document Type: Article

References (33)

1. Martini CH, Boon M, Bevers RF, Aarts LP, Dahan A,. Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. British Journal of Anaesthesia 2014; 112: 498-505.
2. Dubois PE, Putz L, Jamart J, Marotta ML, Gourdin M, Donnez O,. Deep neuromuscular block improves surgical conditions during laparoscopic hysterectomy: a randomised controlled trial. European Journal of Anaesthesiology 2014; 31: 430-6.
3. Gaszynski T, Szewczyk T, Gaszynski W,. Randomized comparison of sugammadex and neostigmine for reversal of rocuronium-induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia 2012; 108: 236-9.
4. Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gõmez JA,. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and Analgesia 2010; 110: 64-73.
5. Pühringer FK, Rex C, Sielenkämper AW, et al., Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008; 109: 188-97.
6. Cammu G, De Kam PJ, Demeyer I, et al., Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. British Journal of Anaesthesia 2008; 100: 373-9.
7. Gijsenbergh F, Ramael S, Houwing N, van Iersel T,. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695-703.
8. Nightingale CE, Margarson MP, Shearer E, et al., Peri-operative management of the obese surgical patient 2015. Anaesthesia 2015; 70: 859-76.
9. Van Lancker P, Dillemans B, Bogaert T, Mulier JP, De Kock M, Haspeslagh M,. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia 2011; 66: 721-5.
10. Llauradõ S, Sabaté A, Ferreres E, Camprubí I, Cabrera A,. Sugammadex ideal body weight dose adjusted by level of neuromuscular blockade in laparoscopic bariatric surgery. Anesthesiology 2012; 117: 93-8.
11. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
12. Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J,. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiologica Scandinavica 2007; 51: 789-808.
13. Claudius C, Skovgaard LT, Viby-Mogensen J,. Is the performance of acceleromyography improved with preload and normalization? A comparison with mechanomyography. Anesthesiology 2009; 110: 1261-70.
14. Viby-Mogensen J, Engbaek J, Eriksson LI, et al., Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiologica Scandinavica 1996; 40: 59-74.
15. Eleveld DJ, Kuizenga K, Proost JH, Wierda JM,. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesthesia and Analgesia 2007; 104: 582-4.
16. Duvaldestin P, Kuizenga K, Saldien V, et al., A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium-or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesthesia and Analgesia 2010; 110: 74-82.
17. Plaud B, Debaene B, Donati F, Marty J,. Residual paralysis after emergence from anesthesia. Anesthesiology 2010; 112: 1013-22.
18. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B,. Quantification of lean body weight. Clinical Pharmacokinetics 2005; 44: 1051-65.
19. Gepts E,. Pharmacokinetic concepts for TCI anaesthesia. Anaesthesia 1998; 53 (Suppl. 1): 4-12.
20. Viby-Mogensen J, Howardy-Hansen P, Chraemmer-Jørgensen B, Ording H, Engbaek J, Nielsen A,. Posttetanic count (PTC): a new method of evaluating an intense nondepolarizing neuromuscular blockade. Anesthesiology 1981; 55: 458-61.
21. Curtis R, Lomax S, Patel B,. Use of sugammadex in a "can't intubate, can't ventilate" situation. British Journal of Anaesthesia 2012; 108: 612-4.
22. Paton L, Gupta S, Blacoe D,. Successful use of sugammadex in a "can't ventilate" scenario. Anaesthesia 2013; 68: 861-4.
23. Jones RK, Caldwell JE, Brull SJ, Soto RG,. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008; 109: 816-24.
24. Geldner G, Niskanen M, Laurila P, et al., A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia 2012; 67: 991-8.
25. Fuchs-Buder T, Meistelman C, Alla F, Grandjean A, Wuthrich Y, Donati F,. Antagonism of low degrees of atracurium-induced neuromuscular blockade. Anesthesiology 2010; 112: 34-40.
26. Schaller SJ, Fink H, Ulm K, Blobner M,. Sugammadex and neostigmine dose- finding study for reversal of shallow residual neuromuscular block. Anesthesiology 2010; 113: 1054-60.
27. Pongrácz A, Szatmári S, Nemes R, Fülesdi B, Tassonyi E,. Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train-of-four stimulation. Anesthesiology 2013; 119: 36-42.
28. Pandit JJ, Andrade J, Bogod DG, et al., The 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: summary of main findings and risk factors. Anaesthesia 2014; 69: 1089-101.
29. Cook TM, Andrade J, Bogod DG, et al., The 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: patient experiences, human factors, sedation, consent and medicolegal issues. Anaesthesia 2014; 69: 1102-16.
30. Le Corre F, Nejmeddine S, Fatahine C, Tayar C, Marty J, Plaud B,. Recurarization after sugammadex reversal in an obese patient. Canadian Journal of Anaesthesia 2011; 58: 944-7.
31. Kotake Y, Ochiai R, Suzuki T, et al., Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesthesia and Analgesia 2013; 117: 345-51.
32. Checketts MR, Alladi R, Ferguson K, et al., Recommendations for standards of monitoring during anaesthesia and recovery 2015: Association of Anaesthetists of Great Britain and Ireland. Anaesthesia 2016; 71: 85-93.
33. Rodney G, Raju PKBC, Ball DR,. Not just monitoring; a strategy for managing neuromuscular blockade. Anaesthesia 2015; 70: 1105-9.